Aldeyra Therapeutics Inc (ALDX) is trading down at $0.65 (-3.73%), as of the latest quote. It operates in the Health Care sector.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Operating income | −$18.7M | −$22.5M | −$39.7M | −$63.1M | −$36.4M | −$56.2M | −$62.7M | −$42.8M | −$60.1M | −$35.3M |
| Net income | −$18.7M | −$22.3M | −$38.9M | −$60.8M | −$37.6M | −$57.8M | −$62.0M | −$37.5M | −$55.9M | −$33.8M |
| EPS (diluted) | −$1.65 | −$1.40 | −$1.79 | −$2.24 | −$1.11 | −$1.07 | −$1.06 | −$0.64 | −$0.94 | −$0.56 |
| Balance sheet | ||||||||||
| Cash and equivalents | $12.0M | $20.0M | $47.4M | $44.4M | $77.9M | $229.8M | $144.4M | $142.8M | $54.5M | $70.0M |
| Total assets | $25.2M | $44.2M | $95.1M | $75.5M | $83.4M | $233.1M | $181.3M | $148.3M | $104.6M | $72.1M |
| Total liabilities | $3.54M | $4.57M | $8.47M | $27.4M | $23.8M | $27.4M | $30.3M | $28.5M | $33.6M | $27.8M |
| Long-term debt | $1.24M | $1.22M | $16.0M | $14.5M | $11.4M | $15.5M | $14.9M | $0 | $15.0M | $0 |
| Shareholders' equity | $21.6M | $39.6M | $86.6M | $48.1M | $59.5M | $205.7M | $151.0M | $119.8M | $71.0M | $44.3M |
| Cash flow | ||||||||||
| Operating cash flow | −$15.1M | −$19.2M | −$29.9M | −$45.0M | −$37.5M | −$42.6M | −$56.6M | −$30.3M | −$43.2M | −$33.3M |
| Capital expenditure | $11.8K | $24.8K | $263.0K | $9.53K | — | $7.81K | $16.3K | $0 | — | — |
| Free cash flow | −$15.2M | −$19.2M | −$30.1M | −$45.0M | — | −$42.6M | −$56.7M | −$30.3M | — | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$16.1M | −$16.6M | −$10.4M | −$10.2M | −$8.00M | −$6.67M | −$3.55M | −$5.85M |
| Net income | −$15.1M | −$15.8M | −$9.93M | −$9.77M | −$7.69M | −$6.46M | −$3.45M | −$5.45M |
| EPS (diluted) | −$0.25 | −$0.27 | −$0.17 | −$0.16 | −$0.13 | −$0.10 | −$0.06 | −$0.09 |
| Balance sheet | ||||||||
| Cash and equivalents | $68.1M | $54.5M | $50.4M | $41.2M | $59.3M | $70.0M | $65.0M | $45.1M |
| Total assets | $117.3M | $104.6M | $93.2M | $85.0M | $77.8M | $72.1M | $66.5M | $47.5M |
| Total liabilities | $32.2M | $33.6M | $29.6M | $29.7M | $28.6M | $27.8M | $24.3M | $9.66M |
| Long-term debt | $15.0M | $15.0M | $15.1M | $0 | $0 | $0 | $0 | — |
| Shareholders' equity | $85.1M | $71.0M | $63.6M | $55.3M | $49.2M | $44.3M | $42.2M | $37.9M |
| Cash flow | ||||||||
| Operating cash flow | −$7.97M | −$12.0M | −$12.5M | −$8.56M | −$7.02M | −$5.30M | −$5.11M | −$4.59M |
From Aldeyra Therapeutics Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Aldeyra Therapeutics Inc in our feed yet.